Biopsy follow-up of prostate-specific antigen tests.

about

Androgen receptor: structure, role in prostate cancer and drug discovery.Five-year downstream outcomes following prostate-specific antigen screening in older men

P2860

Q36063723-69EC910E-3C15-483E-B409-02BAFE3CEB99 Q37017183-2C7ABB87-41FC-4914-AA6E-8FB338E82CFA

P2860

Biopsy follow-up of prostate-specific antigen tests.

Item

http://www.wikidata.org/entity/Q36567436

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Biopsy follow-up of prostate-specific antigen tests.

@ast

Biopsy follow-up of prostate-specific antigen tests.

@en

type

Item

label

Biopsy follow-up of prostate-specific antigen tests.

@ast

Biopsy follow-up of prostate-specific antigen tests.

@en

prefLabel

Biopsy follow-up of prostate-specific antigen tests.

@ast

Biopsy follow-up of prostate-specific antigen tests.

@en

P1476

Biopsy follow-up of prostate-specific antigen tests.

@en

P2093

David C Grossman

http://www.w3.org/2001/XMLSchema#string

Diana S M Buist

http://www.w3.org/2001/XMLSchema#string

Jian Ma

http://www.w3.org/2001/XMLSchema#string

Robert J Reid

http://www.w3.org/2001/XMLSchema#string

Ruth Etzioni

http://www.w3.org/2001/XMLSchema#string

Steven B Zeliadt

http://www.w3.org/2001/XMLSchema#string

P2860

Mortality results from a randomized prostate-cancer screening trial

Screening and prostate-cancer mortality in a randomized European study

Risk adjustment using automated ambulatory pharmacy data: the RxRisk model.

Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force.

Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort

Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.

What's the relative risk? A method to directly estimate risk ratios in cohort studies of common outcomes.

What happens after an elevated PSA test: the experience of 13,591 veterans.

Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.

P304

37-43

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.AMEPRE.2011.08.024

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22176844

http://www.w3.org/2001/XMLSchema#string

P932

3556898

http://www.w3.org/2001/XMLSchema#string

Biopsy follow-up of prostate-specific antigen tests.

about

P2860

P2860

Biopsy follow-up of prostate-specific antigen tests.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932